Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody–drug conjugates come of age in oncology
Charles Dumontet, Janice M. Reichert, Peter D. Senter, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 641-661
Closed Access | Times Cited: 346

Showing 1-25 of 346 citing articles:

Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 172
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 68
Extracellular targeted protein degradation: an emerging modality for drug discovery
James A. Wells, Kaan Kumru
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 2, pp. 126-140
Closed Access | Times Cited: 64
Principles and therapeutic applications of adaptive immunity
Hongbo Chi, Marion Pepper, Paul G. Thomas
Cell (2024) Vol. 187, Iss. 9, pp. 2052-2078
Open Access | Times Cited: 60
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 54
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 45
Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy
Shuxin Yan, Jintong Na, Xiyu Liu, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 248-248
Open Access | Times Cited: 31
Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 30
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 25
Exploiting ferroptosis vulnerabilities in cancer
Toshitaka Nakamura, Marcus Conrad
Nature Cell Biology (2024) Vol. 26, Iss. 9, pp. 1407-1419
Closed Access | Times Cited: 24
crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer
Yutian Zou, Anli Yang, Bo Chen, et al.
Drug Resistance Updates (2024) Vol. 77, pp. 101126-101126
Closed Access | Times Cited: 21
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 19
Peptide–Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics
Trevor T. Dean, Juliet Jelú-Reyes, A’Lester C. Allen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 1641-1661
Closed Access | Times Cited: 17
Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer
Wenjing Xue, Caili Xu, Kaiqi Zhang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 17
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Syed Faheem Askari Rizvi, Lin‐Jie Zhang, Haixia Zhang, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 2, pp. 309-334
Open Access | Times Cited: 16
Recent strategies for evoking immunogenic Pyroptosis in antitumor immunotherapy
Zhangxin He, Dexiang Feng, Chaoji Zhang, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 375-394
Open Access | Times Cited: 15
Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?
Masaya Yamazaki, Takatsugu Ishimoto
Cancer Science (2025)
Open Access | Times Cited: 3
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Avanish Mishra, Shih‐Bo Huang, Taronish D. Dubash, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 35
ADCdb: the database of antibody–drug conjugates
Liteng Shen, Xiuna Sun, Zhen Chen, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1097-D1109
Open Access | Times Cited: 31
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities
Nicole Machado, Lisa C. Heather, Adrian L. Harris, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 6, pp. 897-899
Open Access | Times Cited: 23
Insights into Targeted and Stimulus‐Responsive Nanocarriers for Brain Cancer Treatment
Zahra Abousalman‐Rezvani, Ahmed Refaat, Pouya Dehghankelishadi, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 12
Open Access | Times Cited: 14
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
Meiting Chen, Riqing Huang, R.C. Chen, et al.
The Oncologist (2024) Vol. 29, Iss. 8, pp. e957-e966
Open Access | Times Cited: 12
Spleen-targeted delivery systems and strategies for spleen-related diseases
Ziyao Huang, Kedong Sun, Zhenyu Luo, et al.
Journal of Controlled Release (2024) Vol. 370, pp. 773-797
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top